ECSP10010723A - Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso - Google Patents
Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y usoInfo
- Publication number
- ECSP10010723A ECSP10010723A EC2010010723A ECSP10010723A ECSP10010723A EC SP10010723 A ECSP10010723 A EC SP10010723A EC 2010010723 A EC2010010723 A EC 2010010723A EC SP10010723 A ECSP10010723 A EC SP10010723A EC SP10010723 A ECSP10010723 A EC SP10010723A
- Authority
- EC
- Ecuador
- Prior art keywords
- multivally
- meningococo
- manufacturing
- membrane vesicle
- external membrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Abstract
La presente tecnología presenta una combinación de vesículas nativas de la membrana externa (NOMV) de por lo menos una cepa genéticamente modificada de la Neisseria que proporciona inmunidad protectora contra la enfermedad del meningococo, de preferencia la enfermedad del meningococo del subtipo B. La presente tecnología además presenta los métodos para la inmunización de un animal o un humano en contra de la enfermedad del meningococo que comprende la administración de la composición de la vacuna del presente invento
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5746208P | 2008-05-30 | 2008-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010723A true ECSP10010723A (es) | 2011-05-31 |
Family
ID=41444870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010723A ECSP10010723A (es) | 2008-05-30 | 2010-12-27 | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso |
Country Status (19)
Country | Link |
---|---|
US (2) | US9387239B2 (es) |
EP (1) | EP2296699A4 (es) |
JP (2) | JP5723768B2 (es) |
KR (1) | KR20110053314A (es) |
CN (1) | CN102105166A (es) |
AU (1) | AU2009262893B2 (es) |
BR (1) | BRPI0913268A2 (es) |
CA (1) | CA2726465A1 (es) |
CO (1) | CO6341569A2 (es) |
CR (1) | CR11812A (es) |
DO (1) | DOP2010000364A (es) |
EC (1) | ECSP10010723A (es) |
IL (1) | IL209660A0 (es) |
MX (1) | MX2010012999A (es) |
NZ (1) | NZ589812A (es) |
RU (1) | RU2477145C2 (es) |
UA (1) | UA99659C2 (es) |
WO (1) | WO2009158142A1 (es) |
ZA (1) | ZA201008548B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2270172B1 (en) | 1999-05-19 | 2016-01-13 | GlaxoSmithKline Biologicals SA | Combination neisserial compositions |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
US20130011429A1 (en) * | 2010-03-10 | 2013-01-10 | Jan Poolman | Immunogenic composition |
HUE052850T2 (hu) * | 2010-08-23 | 2021-05-28 | Wyeth Llc | Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények |
ES2585328T5 (es) | 2010-09-10 | 2022-12-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
AU2011300418B2 (en) * | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
GB201015132D0 (en) * | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
CA2846290A1 (en) | 2011-08-31 | 2013-03-07 | Children's Hospital & Research Center Oakland | Engineered sequences to facilitate expression of antigens in neisseria and methods of use |
CN104114706A (zh) | 2012-02-02 | 2014-10-22 | 诺华股份有限公司 | 用于脑膜炎球菌中增加的蛋白表达的启动子 |
WO2013132040A2 (en) * | 2012-03-08 | 2013-09-12 | Novartis Ag | In vitro potency assay for protein-based meningococcal vaccines |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
KR101452830B1 (ko) * | 2012-04-06 | 2014-10-21 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
EP2897635A1 (en) | 2012-09-18 | 2015-07-29 | Novartis AG | Outer membrane vesicles |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
EP3263695A1 (en) * | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
BE1025443B1 (fr) * | 2016-11-25 | 2019-02-28 | Glaxosmithkline Biologicals Sa | CONJUGUES nOMV-ANTIGENE ET LEUR UTILISATION |
US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN107961369B (zh) * | 2017-03-22 | 2020-08-11 | 武汉博沃生物科技有限公司 | 多价脑膜炎球菌缀合疫苗及其制备方法 |
CN113151354B (zh) * | 2021-03-22 | 2022-03-08 | 中国农业科学院兰州兽医研究所 | 一种用于条件性敲除目的基因的载体及条件性敲除目的基因的方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
US4727136A (en) | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
DE4023721A1 (de) | 1990-07-26 | 1992-01-30 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von vakzinen und ihre verwendung |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
US7112332B1 (en) | 1992-10-08 | 2006-09-26 | The United States Of America As Represented By The Secretary Of The Army | Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides |
PT624376E (pt) | 1993-05-13 | 2000-07-31 | American Cyanamid Co | Preparacao e utilizacoes de proteinas de membranas externas deficitarias em los de cocos gram-negativos |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
HUP9901577A3 (en) | 1995-09-18 | 2000-03-28 | Lowell Georg H Cote St Luc | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines |
US6558677B2 (en) * | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
US20030215469A1 (en) | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
WO2000050074A2 (en) | 1999-02-22 | 2000-08-31 | Microbiological Research Authority | Neisserial vaccine compositions and methods |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
MXPA02006962A (es) * | 2000-01-17 | 2002-12-13 | Chiron Spa | Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b. |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
NZ523319A (en) | 2000-06-29 | 2006-01-27 | Glaxosmithkline Biolog Sa | Vaccine compositions comprising Pw, TT, DT and H. influenzae type B (Hib) with a lower dose of Hib (5 mcg) compared with the standard does (10 mcg) |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0024200D0 (en) | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
GB0103169D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
CA2439111A1 (en) | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
EP1374892A1 (en) | 2002-06-28 | 2004-01-02 | Braun, Jan Matthias, Dr. | Medicament for the treatment of diseases due to infection by Neisseria Meningitidis |
ES2537737T3 (es) | 2002-08-02 | 2015-06-11 | Glaxosmithkline Biologicals S.A. | Composiciones de vacuna que comprenden lipooligosacáridos de inmunotipo L2 y/o L3 de Neisseria meningitidis de IgtB |
CU23377A1 (es) | 2003-11-04 | 2009-05-28 | Ct De Ingenieria Genetica Y Biotecnologia | Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes |
US7628995B2 (en) | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
DE602005020608D1 (de) * | 2004-05-11 | 2010-05-27 | Staat Der Nederlanden Vert Doo | NEISSERIA MENINGITIDIS IgtB LOS ALS ADJUVANS |
US7537766B2 (en) * | 2004-08-30 | 2009-05-26 | Wyeth | Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
CA2590974C (en) * | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
ES2337309T5 (es) * | 2006-06-12 | 2013-07-30 | Glaxosmithkline Biologicals S.A. | Vacuna |
-
2009
- 2009-06-01 WO PCT/US2009/045818 patent/WO2009158142A1/en active Application Filing
- 2009-06-01 JP JP2011511892A patent/JP5723768B2/ja not_active Expired - Fee Related
- 2009-06-01 UA UAA201015812A patent/UA99659C2/uk unknown
- 2009-06-01 BR BRPI0913268A patent/BRPI0913268A2/pt not_active IP Right Cessation
- 2009-06-01 CA CA2726465A patent/CA2726465A1/en not_active Abandoned
- 2009-06-01 KR KR1020107029750A patent/KR20110053314A/ko not_active Application Discontinuation
- 2009-06-01 NZ NZ589812A patent/NZ589812A/xx not_active IP Right Cessation
- 2009-06-01 CN CN200980125861XA patent/CN102105166A/zh active Pending
- 2009-06-01 AU AU2009262893A patent/AU2009262893B2/en not_active Ceased
- 2009-06-01 RU RU2010153658/15A patent/RU2477145C2/ru not_active IP Right Cessation
- 2009-06-01 MX MX2010012999A patent/MX2010012999A/es unknown
- 2009-06-01 EP EP09770677.4A patent/EP2296699A4/en not_active Withdrawn
- 2009-06-01 US US12/995,268 patent/US9387239B2/en not_active Expired - Fee Related
-
2010
- 2010-11-25 CR CR11812A patent/CR11812A/es unknown
- 2010-11-26 DO DO2010000364A patent/DOP2010000364A/es unknown
- 2010-11-29 ZA ZA2010/08548A patent/ZA201008548B/en unknown
- 2010-11-30 IL IL209660A patent/IL209660A0/en unknown
- 2010-12-27 EC EC2010010723A patent/ECSP10010723A/es unknown
- 2010-12-29 CO CO10164103A patent/CO6341569A2/es not_active Application Discontinuation
-
2014
- 2014-12-11 JP JP2014250805A patent/JP2015061870A/ja not_active Withdrawn
-
2016
- 2016-07-12 US US15/208,067 patent/US20170100471A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170100471A1 (en) | 2017-04-13 |
EP2296699A4 (en) | 2013-11-13 |
EP2296699A1 (en) | 2011-03-23 |
JP5723768B2 (ja) | 2015-05-27 |
DOP2010000364A (es) | 2011-07-15 |
MX2010012999A (es) | 2012-03-07 |
KR20110053314A (ko) | 2011-05-20 |
CO6341569A2 (es) | 2011-11-21 |
AU2009262893A9 (en) | 2015-05-21 |
CR11812A (es) | 2011-07-06 |
US20110182942A1 (en) | 2011-07-28 |
JP2015061870A (ja) | 2015-04-02 |
UA99659C2 (uk) | 2012-09-10 |
CA2726465A1 (en) | 2009-12-30 |
AU2009262893B2 (en) | 2015-05-21 |
WO2009158142A1 (en) | 2009-12-30 |
AU2009262893A1 (en) | 2009-12-30 |
RU2477145C2 (ru) | 2013-03-10 |
CN102105166A (zh) | 2011-06-22 |
RU2010153658A (ru) | 2012-08-10 |
JP2011521976A (ja) | 2011-07-28 |
US9387239B2 (en) | 2016-07-12 |
IL209660A0 (en) | 2011-02-28 |
BRPI0913268A2 (pt) | 2016-03-15 |
NZ589812A (en) | 2012-08-31 |
ZA201008548B (en) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010723A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso | |
AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
AR118199A2 (es) | Composiciones inmunogénicas de variantes no lipidadas no piruviladas de antígenos orf2086 de neisseria meningitidis, polipéptidos, secuencias de nucleótidos y plásmidos | |
CR11122A (es) | Vacuna de influenza de emulsion de aceite en agua | |
WO2010037395A3 (en) | Mhc multimers in cancer vaccines and immune monitoring | |
CL2007001698A1 (es) | Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis. | |
AR078247A1 (es) | Vacuna de pcsk9 | |
BRPI0607374A2 (pt) | vacinas de vesìculas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis | |
CL2011000513A1 (es) | Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina. | |
AR052625A1 (es) | Nueva composicion | |
CO6362045A2 (es) | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales | |
CA2763359C (en) | New human rotavirus strains and vaccines | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
MY169275A (en) | Method of immunization against the four serotypes of dengue | |
EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
BR112014031386A2 (pt) | vacinas para meningococos do sorogrupo x | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
UA114286C2 (uk) | Спосіб лікування staphylococcus aureus | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. | |
BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
ECSP12011951A (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria | |
WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy | |
AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias |